Login
$IKT
$1.45 -$0.07 (4.61%) Live

$IKT SEC Filings

Filed On Filing
10 Nov 2026 10-Q
10 Nov 2026 8-K: Results of Operations and Financial Condition

WILMINGTON, Del., November 10, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial ...

21 Oct 2026 Form 4: Wasserman Scott M., Director

Granted 310,000 Stock Option (Right to Buy)

21 Oct 2026 Form 3: Wasserman Scott M., Director

No securities owned

20 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

WILMINGTON, Del., October 20, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial H...

08 Sep 2026 8-K: Regulation FD Disclosure

Disclaimer This presentation contains information that may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Inhibikase Therapeutics, Inc. (the “Company” or “w...

26 Aug 2026 8-K: Changes in Registrant's Certifying Accountant

Inhibikase Therapeutics, Inc. - Changes in Registrant’s Certifying Accountant

14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
13 Aug 2026 SCHEDULE 13G/A
11 Aug 2026 S-8
11 Aug 2026 10-Q
11 Aug 2026 8-K: Results of Operations and Financial Condition

WILMINGTON, Del., August 11, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hy...

31 Jul 2026 SCHEDULE 13G/A
31 Jul 2026 Form 4: Ra Capital MANAGEMENT, L.p., 10% owner and 3 others

Disposed of 18,030,000 shares (Other Transaction) · Acquired 18,030,000 Pre-Funded Warrant (Right to Buy) (Other Transaction)

31 Jul 2026 Form 4: Berman Dennis N, Director

Received 21,854 shares by exercise or conversion ($27.5K)

29 Jul 2026 8-K: Unregistered Sales of Equity Securities

Inhibikase Therapeutics, Inc. , a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the “Holder”...

28 Jul 2026 SCHEDULE 13G
23 Jul 2026 8-K: Regulation FD Disclosure

WILMINGTON, Del., July 23, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), today announced that the U...

17 Jul 2026 Form 3: Ra Capital MANAGEMENT, L.p., 10% owner and 3 others

Holds 25,000,000 shares of Common Stock

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support